Drug intelligence / Profile preview

Propofol Lipuro 1%

Development stage
Unknown
Lead developer
B. Braun
Modality
Small Molecules
Administration
Intravenous
01

Overview

Propofol Lipuro 1% is a short-acting intravenous general anesthetic and sedative formulated as a 1% (10 mg/mL) lipid emulsion. Developed and manufactured by B. Braun, this specific formulation uses a mixture of medium-chain and long-chain triglycerides (MCT/LCT) to improve the tolerability of the injection, specifically aiming to reduce the pain on injection commonly associated with standard propofol emulsions. The active ingredient, propofol, is a small molecule that functions as a positive allosteric modulator of GABA-A receptors in the central nervous system, thereby enhancing inhibitory neurotransmission to induce and maintain anesthesia or sedation. It is widely approved in Europe and other international markets for use in adults and children as young as one month for general anesthesia and for sedation in patients over 16 years old in the intensive care unit.

Brand names
Propofol Lipuro 1%Propofol Lipuro
Other names
propofol 1% lipid emulsion2,6-diisopropylphenol
02

Targets

GABAA (Gamma-aminobutyric acid receptor)LTCC (Voltage-gated calcium channel (L-type))NMDAR (Glutamate receptor ionotropic, NMDA)Nicotinic Acetylcholine ReceptorPKC (Protein kinase C family)GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on Propofol Lipuro 1%.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Propofol Lipuro 1%.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call